Enpatoran placebo

DRUG2 trials

Sponsors

Merck Healthcare KGaA

Conditions

DermatomyositisPolymyositisSystemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)

Phase 2

A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants receiving Standard of Care

CompletedCTIS2022-501351-82-00

Merck Healthcare KGaADermatomyositis, Polymyositis

Start: 2023-05-23End: 2025-05-21Target: 15Updated: 2025-06-26

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus (Subacute Cutaneous Lupus Erythematosus and/or Discoid Lupus Erythematosus) Participants Receiving Standard of Care

CompletedCTIS2024-510872-18-00

Merck Healthcare KGaASystemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)

Start: 2022-05-09End: 2025-01-27Target: 127Updated: 2025-01-27